Kenvue Inc.
Rank #198ValueKVUE · NYSE · Consumer Defensive
Kenvue Inc. (KVUE) — Rank #198 by gross profitability (GP/assets 0.33) · ROE 13.9% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0001944048 · all metrics point-in-time as of the filing date.
About
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.
Show moreShow less
It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc.
was incorporated in 2022 and is headquartered in Summit, New Jersey.
- Industry
- Household & Personal Products
- Sector
- Consumer Defensive
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- January 3
- Website
- kenvue.com
Financials
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2025-12-28filed 2026-02-20 | 2024-12-29filed 2025-02-24 | 2023-12-31filed 2024-03-01 | 2023-01-01filed 2024-03-01 |
|---|---|---|---|---|
| Operating | ||||
| Depreciation & amortization | 557.0 | 622.0 | 627.0 | 644.0 |
| Stock-based compensation | 136.0 | 254.0 | 188.0 | 137.0 |
| Change in receivables | 112.0 | 218.0 | (44.0) | 142.0 |
| Change in inventory | 12.0 | (182.0) | (349.0) | 582.0 |
| Change in payables | — | — | 390.0 | 52.0 |
| Operating cash flow | 2,197.0 | 1,769.0 | 3,168.0 | 2,525.0 |
| Investing | ||||
| Capital expenditures | 475.0 | 434.0 | 469.0 | — |
| Investing cash flow | (436.0) | (425.0) | (488.0) | (390.0) |
| Financing | ||||
| Share repurchases | 197.0 | 235.0 | — | — |
| Dividends paid | 1,581.0 | 1,552.0 | 766.0 | 0.0 |
| Financing cash flow | (1,837.0) | (1,565.0) | (2,527.0) | (1,583.0) |
| Summary | ||||
| Free cash flow | 1,722.0 | 1,335.0 | 2,699.0 | 2,699.0 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?